1 / 71

Malignant Breast Disease

Malignant Breast Disease. Juhi Asad, DO Alison Estrabrook, MD Dept. of Breast Surgery. Breast Cancer. Over 180,000 new cases ~62,000 are in situ (30%) 2 nd leading cause of all cancer deaths 80% of cases occur >50yo. Pre-op. History Physical Imaging Diagnosis Treatment options.

tannar
Download Presentation

Malignant Breast Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Malignant Breast Disease Juhi Asad, DO Alison Estrabrook, MD Dept. of Breast Surgery

  2. Breast Cancer • Over 180,000 new cases • ~62,000 are in situ (30%) • 2nd leading cause of all cancer deaths • 80% of cases occur >50yo

  3. Pre-op • History • Physical • Imaging • Diagnosis • Treatment options

  4. Surgical Options • Partial Mastectomy (lumpectomy) • Total Mastectomy • Reconstruction • Sentinel lymph node biopsy • Axillary lymph node dissection

  5. Surgical Treatment • Partial Mastectomy • Radiation therapy • Free margins • Aesthetic results • NSABP B-06 • no significant difference in survival between MRM, lump w/radiaton, and lump w/o radiation

  6. Partial Mastectomy • Contraindications • Size relative to breast • Multifocality • Early pregnancy • Inability to receive radiation • Connective tissue disease • Prior radiation

  7. Surgical Treatment • Radial Mastectomy • Historical – mid 70s • Breast, pectoralis, regional lymph nodes along axillary vein to costoclavicular ligament

  8. Surgical Treatment • Total Mastectomy axillary dissection • TM + Skin sparing w/reconstruction

  9. Reconstruction • Implants • Flaps • TRAM • Latissimus • DIEP

  10. Tissue Expanders

  11. TRAM

  12. Oncoplastic Surgery

  13. Preop 4 Days Postop

  14. Surgical Treatment • Sentinel Node Biopsy • The 1st node in the ipsilateral axilla to drain the tumor • >97% concordance rate

  15. Sentinel Lymph Node • Contraindications • Clinically positive lymph nodes

  16. Sentinel Lymph Node • Technetium-99m sulfur colloid • Intradermal : peritumoral or periareolar • Isosulfan blue dye • Intraparenchymal Problems: • Anaphylactic reaction (1-3%) • Skin discoloration • Contraindicated in pregnancy

  17. Sentinel Lymph Node • Intra-op evaluation • Frozen section • Touch prep • Benefits over axillary node dissection • more accurate pathology • less lymphedema – ( very rare vs 10-50%) • less sensory disturbances • less shoulder dysfunction • less wound infection • less incisional pain

  18. Axillary Lymph Node Dissection • Indications • Clinically + nodes • + SLN • Level I & II

  19. Pathology • DCIS • Invasive Ductal • Invasive Lobular

  20. DCIS • 200% b/w 1983-1992 • 15-30% all screen-detected tumors • Diagnosis • Screening mammogram • Microcalcifications • Linear, heterogenous • Biopsy • Stereotactic • Open biopsy

  21. DCIS • Treatment • Partial Mastectomy • Followed by radiation +/- hormonal therapy • Total mastectomy • Diffuse disease • Multifocal • Persistent positive margins • Inability to give radiation • Patient choice

  22. DCIS • Sentinel Lymph Node Biopsy • Total Mastectomy • Palpable mass • Microinvasion

  23. DCIS • Radiation Therapy • 50% decrease in recurrence LE • Hormonal Therapy • NSABP B-24 – LE, RT, +TAM vs LE, RT only • TAM – 8.2% incidence of IBTR • Placebo – 13.4% incidence of IBTR

  24. Invasive Ductal Ca • Most common – 50-70% of invasive ca

  25. Invasive Lobular Ca • 10-15% of breast ca • Fail to form masses • Multifocal and multicentric • Bilateral – 20-29%

  26. ILC

  27. T2: 2cm-5cm T3: >5cm T4: extension Staging • Primary Tumor (T) • TX: unable to assess • T0: no evidence of primary tumor • Tis: DCIS, LCIS or Paget’s (nipple only) • T1: <2cm

  28. Regional Lymph Nodes (N) • NX: unable to assess • N0: negative • N1: 1-3 nodes • N2: 4-9 nodes • N3: >10 nodes

  29. Distant metastatsis: (M) • MX: unable to assess • M0: negative • M1: distant mets

  30. Stage 0 Tis, N0, M0 Stage I T1*, N0, M0 Stage IIA T0, N1, M0 T1*, N1, M0 T2, N0, M0 Stage IIB T2, N1, M0 T3, N0, M0 Stage IIIA T0, N2, M0 T1*, N2, M0 T2, N2, M0 T3, N1, M0 T3, N2, M0 Stage IIIB T4, N0, M0 T4, N1, M0 T4, N2, M0 Stage IIIC** Any T, N3, M0 Stage IV Any T, Any N, M1 [Note: T1 includes T1mic] AJCC Staging

  31. 5 year Survival

  32. Adjuvant Therapy • www.adjuvantonline.com • Assess the risks and benefits of additional therapy after surgery

  33. Prognostic Indicators • Hormone Receptors – improved prognosis • ER – 70-80% • PR – indicator for a functional ER receptor • Epidermal growth factor • HER/erbB2 • EGFR • HER2/neu • Cell proliferation & differentiation • erbB2

  34. Prognostic Indicators • P53 – tumor suppressor gene • Overexpression of p53 • Poorer prognosis • Shorter disease-free and survival

  35. Oncotype Dx • ER (+); node (-) • Genetic profile – 21 gene assay • Recurrence score (3 groups) • Low – hormonal therapy • Intermediate – TailorRx trial • Hormonal vs chemo + hormonal • High – chemo + hormonal therapy

  36. Adjuvant Therapy • Hormonal therapy • Antiestrogen therapy – Tamoxifen • Pre & post-menopausal women • Reduces risk of contralateral disease & mets • Side effects • Endometrial ca • Thromoembolic events

  37. Adjuvant Therapy • Hormonal Therapy • Aromastase Inhibitors – blocks the conversion of androstenedione to estrone • Post-menopausal women • ATAC trial – anastrozole decreased the risk of contralateral cancers compared to TAM • Side effects • Bone loss and joint pain

  38. Adjuvant Therapy • Chemotherapy • Size of tumor • Nodal status • ER/PR • HER2/Neu -- Herceptin

More Related